SG11201807913XA - Stabilized soluble pre-fusion rsv f proteins - Google Patents

Stabilized soluble pre-fusion rsv f proteins

Info

Publication number
SG11201807913XA
SG11201807913XA SG11201807913XA SG11201807913XA SG11201807913XA SG 11201807913X A SG11201807913X A SG 11201807913XA SG 11201807913X A SG11201807913X A SG 11201807913XA SG 11201807913X A SG11201807913X A SG 11201807913XA SG 11201807913X A SG11201807913X A SG 11201807913XA
Authority
SG
Singapore
Prior art keywords
international
proteins
archimedesweg
leiden
pct
Prior art date
Application number
SG11201807913XA
Inventor
Anders Krarup
Johannes Langedijk
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11201807913XA publication Critical patent/SG11201807913XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011101111111011011101111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....1 WO 2017/174568 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: DO, A61K 35/12 (2015.01) A61K 39/12 (2006.01) HN, C07K 14/005 (2006.01) KP, MD, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (21) International Application Number: NI, PCT/EP2017/057962 RU, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (22) International Filing Date: TH, 4 April 2017 (04.04.2017) ZA, ZM, ZW. TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English (8 4 ) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 16163810.1 5 April 2016 (05.04.2016) EP TJ, DK, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: JANSSEN VACCINES & PREVENTION LV, B.V. [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL). SM, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: KRARUP, Anders; Archimedesweg 4-6, 2333 GW, KM, ML, MR, NE, SN, TD, TG). CN Leiden (NL). LANGEDIJK, Johannes, Petrus, Declarations under Rule 4.17: Maria; Archimedesweg 4-6, 2333 CN Leiden (NL). — as to applicant's entitlement to apply for and be granted a (74) Agents: MANTEN, Annemieke et al.; Archimedesweg 4- patent (Rule 4.17(11)) 6, 2333 CN Leiden (NL). — of inventorship (Rule 4.17(iv)) = (81) Designated States (unless otherwise indicated, for every Published: kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, — with BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, international search report (Art. 21(3)) = = = = = = = = = = = = 1-1 GO ,tD kin IN ,-1 IN IN ,-1 © ei (54) Title: STABILIZED SOLUBLE PRE-FUSION RSV F PROTEINS C ) ,..,.. (57) : The present invention provides stable pre-fusion respiratory syncitial virus (RSV) F proteins (or fragment thereof), compositions comprising said proteins and uses thereof for the prevention and/or treatment of RSV infection.
SG11201807913XA 2016-04-05 2017-04-04 Stabilized soluble pre-fusion rsv f proteins SG11201807913XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163810 2016-04-05
PCT/EP2017/057962 WO2017174568A1 (en) 2016-04-05 2017-04-04 Stabilized soluble pre-fusion rsv f proteins

Publications (1)

Publication Number Publication Date
SG11201807913XA true SG11201807913XA (en) 2018-10-30

Family

ID=55752165

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807913XA SG11201807913XA (en) 2016-04-05 2017-04-04 Stabilized soluble pre-fusion rsv f proteins

Country Status (29)

Country Link
US (2) US11155583B2 (en)
EP (2) EP3439672B1 (en)
JP (2) JP7088841B2 (en)
KR (2) KR20220041966A (en)
CN (2) CN116063551A (en)
AU (2) AU2017248021B2 (en)
BR (1) BR112018070013A2 (en)
CA (1) CA3018941A1 (en)
CL (1) CL2018002826A1 (en)
CY (1) CY1124019T1 (en)
DK (1) DK3439672T3 (en)
EA (2) EA039095B1 (en)
ES (1) ES2858315T3 (en)
HR (1) HRP20210113T1 (en)
HU (1) HUE053027T2 (en)
IL (2) IL291604B2 (en)
LT (1) LT3439672T (en)
MA (2) MA43763B1 (en)
MD (1) MD3439672T2 (en)
MX (2) MX2018012094A (en)
MY (1) MY190320A (en)
PE (1) PE20190420A1 (en)
PH (1) PH12018501962A1 (en)
PL (1) PL3439672T3 (en)
PT (1) PT3439672T (en)
RS (1) RS61456B1 (en)
SG (1) SG11201807913XA (en)
SI (1) SI3439672T1 (en)
WO (1) WO2017174568A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10899800B2 (en) * 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
BR112018070013A2 (en) * 2016-04-05 2019-02-05 Janssen Vaccines & Prevention Bv stabilized soluble fusion rsv f proteins
JP7233928B2 (en) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine against RSV
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN115947873A (en) 2017-04-04 2023-04-11 华盛顿大学 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and uses thereof
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
JOP20210106A1 (en) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V Stabilized pre-fusion rsv f proteins
BR112022019411A2 (en) 2020-04-02 2022-12-06 Janssen Vaccines & Prevention Bv STABILIZED VACCINE COMPOSITIONS
MX2023000024A (en) 2020-06-29 2023-04-12 Janssen Vaccines & Prevention Bv Vaccine combination against respiratory syncytial virus infection.
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
EP4294436A1 (en) 2021-02-19 2023-12-27 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb fantigens
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69638058D1 (en) 1995-06-15 2009-11-26 Crucell Holland Bv Packaging systems for human recombinant adenoviruses for gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
AU3447097A (en) 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
FR2751343B1 (en) 1996-07-16 1998-12-18 Transgene Sa PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE69933433T2 (en) 1998-02-17 2007-08-23 Schering Corp. VIRUS-CONTAINING COMPOSITIONS AND METHODS FOR CONCENTRATING VIRUS PREPARATIONS
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ATE421337T1 (en) 1998-11-16 2009-02-15 Introgen Therapeutics Inc ADENOVIRUS FORMULATIONS FOR GENE THERAPY
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
PT1818408E (en) 1999-05-17 2011-11-15 Crucell Holland Bv Recombinant adenovirus of the ad11 serotype
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
EP1287159A4 (en) 2000-05-08 2005-02-09 Davisco Foods Int Inc Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
WO2003049764A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
RU2004125283A (en) 2002-01-18 2005-06-10 Шеринг Акциенгезельшафт (De) STABILIZED Adenovirus Compositions
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ATE447037T1 (en) 2002-04-25 2009-11-15 Crucell Holland Bv MEANS AND METHOD FOR PRODUCING ADENOVIRUS VECTORS
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
ATE494362T1 (en) 2002-05-14 2011-01-15 Merck Sharp & Dohme METHOD FOR PURIFYING ADENOVIRUS
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1585964A4 (en) 2002-08-28 2008-07-16 Introgen Therapeutics Inc Chromatographic methods for adenovirus purification
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP1711518B1 (en) 2004-01-23 2009-11-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Chimpanzee adenovirus vaccine carriers
DE602005015332D1 (en) 2004-02-23 2009-08-20 Crucell Holland Bv Method for cleaning viruses
CN101155915B (en) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 Virus purification using ultrafiltration
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20090110695A1 (en) 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
BRPI0821532A2 (en) 2007-12-24 2015-06-16 Id Biomedical Corp Quebec Recombinant rsv antigens
MX2011004292A (en) 2008-11-03 2011-05-31 Crucell Holland Bv Method for the production of adenoviral vectors.
WO2010086189A2 (en) 2009-02-02 2010-08-05 Okairòs Ag, Switzerland Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US8889146B2 (en) 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
EP2445526B1 (en) 2009-06-24 2016-05-11 GlaxoSmithKline Biologicals S.A. Recombinant rsv antigens
EP3988115A3 (en) 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
CA2770737C (en) 2009-08-13 2020-05-12 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
CN102575233B (en) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 Process for adenovirus purification from high cell density cultures
DK2488636T3 (en) 2009-10-15 2014-06-23 Crucell Holland Bv PROCEDURE FOR CLEANING ADENOVIRUS PARTICLES FROM HIGH CELL DENSITY CULTURES
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CA2786835C (en) 2010-02-15 2021-08-31 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
CN106188284B (en) 2010-07-09 2020-05-08 扬森疫苗与预防公司 Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
HUE027839T2 (en) 2012-03-12 2016-11-28 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
CA2867950C (en) 2012-03-22 2023-02-21 Crucell Holland B.V. Vaccine against rsv
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
KR102450375B1 (en) 2013-03-13 2022-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Prefusion rsv f proteins and their use
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US9856313B2 (en) * 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
EP3567052A1 (en) 2013-04-15 2019-11-13 Janssen Vaccines & Prevention B.V. Human antibodies binding to rsv g protein
AU2014255864B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
US10899800B2 (en) * 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3024483B1 (en) 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
AP2016009154A0 (en) 2013-09-19 2016-04-30 Crucell Holland Bv Improved adenovirus formulations
JP7233928B2 (en) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine against RSV
BR112018070013A2 (en) * 2016-04-05 2019-02-05 Janssen Vaccines & Prevention Bv stabilized soluble fusion rsv f proteins
JP2020533367A (en) 2017-09-15 2020-11-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Safe method of inducing immunity to RSV

Also Published As

Publication number Publication date
AU2021209185A1 (en) 2021-08-19
MX2022015257A (en) 2023-01-11
IL262108B (en) 2022-12-01
KR102506895B1 (en) 2023-03-08
IL262108B2 (en) 2023-04-01
JP7362819B2 (en) 2023-10-17
BR112018070013A2 (en) 2019-02-05
EP3808374A1 (en) 2021-04-21
PE20190420A1 (en) 2019-03-19
LT3439672T (en) 2021-01-25
MX2018012094A (en) 2019-01-10
EA201892251A1 (en) 2019-03-29
PL3439672T3 (en) 2021-06-14
CL2018002826A1 (en) 2018-11-16
EP3439672A1 (en) 2019-02-13
KR20220041966A (en) 2022-04-01
EA202191622A1 (en) 2022-01-31
IL291604B2 (en) 2024-02-01
RS61456B1 (en) 2021-03-31
SI3439672T1 (en) 2021-02-26
KR20180131584A (en) 2018-12-10
IL291604A (en) 2022-05-01
HRP20210113T1 (en) 2021-03-05
MA43763B1 (en) 2021-03-31
DK3439672T3 (en) 2021-02-15
MY190320A (en) 2022-04-13
IL262108A (en) 2018-11-29
ES2858315T3 (en) 2021-09-30
PH12018501962A1 (en) 2019-06-24
MA52910A (en) 2021-04-21
HUE053027T2 (en) 2021-06-28
CN116063551A (en) 2023-05-05
CY1124019T1 (en) 2022-05-27
US20220089652A1 (en) 2022-03-24
CA3018941A1 (en) 2017-10-12
IL291604B1 (en) 2023-10-01
MA43763A (en) 2019-02-13
AU2017248021B2 (en) 2021-08-12
EA039095B1 (en) 2021-12-03
WO2017174568A1 (en) 2017-10-12
US20190119330A1 (en) 2019-04-25
AU2021209185B2 (en) 2023-06-01
EP3439672B1 (en) 2020-11-25
AU2017248021A1 (en) 2018-10-04
JP2022101561A (en) 2022-07-06
MD3439672T2 (en) 2021-04-30
PT3439672T (en) 2021-02-24
CN109069616A (en) 2018-12-21
JP7088841B2 (en) 2022-06-21
JP2019513377A (en) 2019-05-30
US11155583B2 (en) 2021-10-26

Similar Documents

Publication Publication Date Title
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201807912SA (en) Vaccine against rsv
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201808108XA (en) Synthesis of indazoles
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201805001UA (en) Method of treating influenza a
SG11201811706RA (en) Process for the preparation of microcapsules
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201809594WA (en) Nicotine particles and compositions
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201810318RA (en) Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses
SG11201900021PA (en) Methods and compositions for the treatment of cancer